Healthcare products company West Pharmaceutical Services (NYSE: WST) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 13.8% year on year to $872.3 million. Guidance for next quarter’s revenue was better than expected at $827.5 million at the midpoint, 0.8% above analysts’ estimates. Its non-GAAP profit of $2.37 per share was 13.9% above analysts’ consensus estimates.

Is now the time to buy WST? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

West Pharmaceutical Services posted a solid Q2, with revenue and adjusted earnings per share exceeding Wall Street expectations, while the market response remained muted. Management attributed the outperformance to robust growth in its Proprietary Products, particularly high-value product (HVP) components for biologics and biosimilars. CEO Eric Green highlighted, “Our performance was driven by the execution of our strategy and continued operational excellence initiatives,” pointing to the company’s strong recovery following a cyber incident and the expansion of advanced containment solutions as key factors supporting the quarter.

Looking forward, West Pharmaceutical Services’ improved guidance is underpinned by continued momentum in biologics and biosimilars, an accelerating shift to HVP upgrades, and growing demand for GLP-1 therapies. CFO Robert McMahon emphasized that both GLP-1 and non-GLP-1 HVP components are expected to maintain high-teens organic growth, supported by broader adoption in emerging markets and new drug launches. Management also highlighted that ongoing mix shifts toward HVP products and operational improvements should drive further margin expansion, despite some inflationary pressures from higher commodity prices.

Key Insights from Management’s Remarks

Management attributed the quarter’s results to strong execution in biologics, increased adoption of HVP components, and a positive mix shift from regulatory-driven upgrades and GLP-1 therapy growth.

• Biologics and biosimilar momentum: Management cited over 90% participation in new biologic launches, with biologics accounting for the largest share of HVP component growth. The complexity and regulatory requirements of these drugs drive demand for West’s advanced containment solutions, such as NovaPure and FluroTec.
• Annex 1 upgrades drive mix shift: The ongoing implementation of Europe’s Annex 1 contamination control standards accelerated customer upgrades to higher-value products. Management reported nearly 800 active Annex 1-related projects, up 50% year-over-year, with early signs of similar regulatory-driven demand in the U.S. and other geographies.
• GLP-1 therapy expansion: High-value components for GLP-1 therapies (used in diabetes and obesity treatments) grew high teens, aided by increased adoption in the U.S. and emerging markets. Management expects continued growth as generic GLP-1s launch globally and new indications expand their use.
• Operational resilience post-cyber incident: The company credited operational excellence initiatives, particularly at its Eschweiler plant, for helping recover quickly from a cyber incident. Productivity improvements enabled West to meet strong demand without major disruption.
• SmartDose divestiture and delivery devices: The completion of the SmartDose 3.5 mL On-Body Delivery System sale shifted focus to other self-injection and administration devices, such as SelfDose and Crystal Zenith, which showed double-digit growth and now contribute more favorably to margins.

Drivers of Future Performance

Management expects high-value products and biologics to continue powering growth, with ongoing margin expansion from product mix and operational improvements.

• Ongoing biologics pipeline strength: Management anticipates sustained demand from new biologic and biosimilar launches, supported by robust win rates and expansion into emerging markets, which should underpin double-digit organic revenue growth.
• Margin expansion from product mix: The continued shift toward HVP components and away from lower-margin standard products is expected to drive operating margin improvements. The recent SmartDose divestiture should further enhance the margin profile in the second half of the year and beyond.
• Inflationary and operational headwinds: While management is confident in offsetting most inflationary pressures through pricing and efficiency initiatives, they acknowledge commodity price increases as a risk. The recovery from the cyber incident is expected to be complete, but West Vantage’s performance will be watched closely as new drug handling business ramps up.

Catalysts in Upcoming Quarters

In the coming quarters, StockStory’s analysts will closely monitor (1) the pace of biologic and biosimilar drug approvals and West’s win rates in complex containment solutions, (2) execution on regulatory-driven HVP upgrades, especially as Annex 1 adoption spreads beyond Europe, and (3) the ramp-up of GLP-1 component sales in emerging markets and for new indications. Progress in operational execution and the performance of the West Vantage segment will also be important metrics for tracking the company’s strategic progress.

West Pharmaceutical Services currently trades at $355.59, in line with $358.72 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

Stocks That Trumped Tariffs

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.